[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:cd276-wt-allele":3},{"name":4,"total":5,"recruiting":6,"trials":7},"CD276 wt Allele",20,16,[8,16,23,29,35,40,47,53,59,65,70,76,82,88,95,101,107,114,120,126],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05142189","Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:16:32.589113Z","2026-07-24T01:27:14.869513Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07680439","Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).",[20],"Phase 2","2026-08-26T02:17:02.694423Z","2026-07-05T03:45:20.443469Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07612176","A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors",[12],"2026-08-26T02:18:23.582895Z","2026-05-29T15:36:40.230934Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07593092","Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors",[12],"2026-08-26T02:15:24.145250Z","2026-05-29T15:36:40.203660Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":27,"content_modified":39},"NCT06347068","Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells",[12],"2026-05-05T02:47:14.272026Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":45,"content_modified":46},"NCT07268053","A Phase 0\u002F1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases",[44],"Early Phase 1","2026-08-26T02:19:29.119921Z","2026-05-05T02:43:28.794018Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06482905","Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:28.000760Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT05474378","B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:35:31.774538Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05366179","Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc",[12],"2026-08-26T02:17:14.343713Z","2026-04-29T02:57:57.149538Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":57,"content_modified":69},"NCT06305299","Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells",[12],"2026-05-05T02:43:28.485998Z",{"nct_id":71,"title":72,"phases":73,"status":13,"updated_at":74,"content_modified":75},"NCT06953089","DB-1311 in Combination With BNT327 or DB-1305 in Advanced\u002FMetastatic Solid Tumors",[20],"2026-08-26T02:19:18.331180Z","2026-06-16T05:54:07.929157Z",{"nct_id":77,"title":78,"phases":79,"status":13,"updated_at":80,"content_modified":81},"NCT04185038","Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma\u002FDiffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors",[12],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:28.903254Z",{"nct_id":83,"title":84,"phases":85,"status":13,"updated_at":86,"content_modified":87},"NCT04897321","B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)",[12],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.511090Z",{"nct_id":89,"title":90,"phases":91,"status":13,"updated_at":93,"content_modified":94},"NCT07189871","177Lu-BetaBart in Patients With Relapsed\u002FRefractory, Locally Advanced Inoperable, or Metastatic Solid Tumors",[92],"Phase 1\u002FPhase 2","2026-08-26T02:17:06.985283Z","2026-05-05T02:43:28.479823Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT07222735","Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed\u002FRefractory Sarcomas",[12],"2026-08-26T02:17:48.768272Z","2026-05-05T02:43:27.273704Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07698899","A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)",[12],"2026-08-26T02:18:49.989941Z","2026-07-19T19:36:05.081790Z",{"nct_id":108,"title":109,"phases":110,"status":111,"updated_at":112,"content_modified":113},"NCT07386002","The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:18.872924Z","2026-05-05T02:43:27.918825Z",{"nct_id":115,"title":116,"phases":117,"status":111,"updated_at":118,"content_modified":119},"NCT07358260","B7-H3.CD28Z.CART in Solid Tumors",[12],"2026-08-26T02:14:59.425132Z","2026-05-05T02:35:31.917175Z",{"nct_id":121,"title":122,"phases":123,"status":111,"updated_at":124,"content_modified":125},"NCT07509034","Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease",[12],"2026-08-26T02:16:48.735701Z","2026-07-19T19:36:05.076294Z",{"nct_id":127,"title":128,"phases":129,"status":130,"updated_at":131,"content_modified":132},"NCT05835687","Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:27.753658Z"]